R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics
Darmstadt, June 7, 2022 – R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. “The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio,” states Christian Dreher, CEO of R-Biopharm. “The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics.”
Upon its establishment in 2006, the Australian company introduced its patented Multiplex Tandem PCR (MT-PCR) on the market. The current technology allows the simultaneous detection of up to 24 pathogens or resistance genes from a single sample, thus shortening the lengthy test procedure in human and animal diagnostics as well as environmental, agricultural, and food analysis. The analysis platform is used in laboratories and hospitals throughout the world for detecting a broad range of diseases.
AusDiagnostics CEO Scott Gilroy said that the transaction marked an exciting new chapter for the company: “Both AusDiagnostics and R-Biopharm AG share the same commitment to innovation in the biotechnology space. This acquisition strengthens AusDiagnostics and will accelerate our global presence. We’ve experienced tremendous, industry-leading growth over the past two years, which has been underpinned by our broad suite of innovative products, talented team, and incredible, loyal customers. Joining the R-Biopharm group will allow us to further build on this and continue to deliver exceptional products and service for our Australian and international customers.”
AusDiagnostics currently has 92 employees with offices in New Zealand, the USA, and Great Britain. Its production facilities in Australia and Great Britain supply a steadily growing network of more than 25 distributors and partners around the world – from which R-Biopharm expects further synergy effects for production as well as international service and support in its clinical diagnostics line.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany’s leading biotechnology companies. It considers itself as a pioneer for health and quality of life. The company´s aspiration is to provide the highest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. Research and development at R-Biopharm has developed agile processes in order to take on new challenges to accompany a steadily growing world population into a new health era with sustainable solutions.
As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of Clinical Diagnostics, Nutrition Care and Food and Feed Analytics. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotechnology company is known for its products that are of high importance for human health. To this end, it unites development, production and sales under one roof and is successfully represented in more than 120 countries worldwide – through 28 subsidiaries and 120 distributors. Founded in 1988, the family-run company employs a total of around 1,300 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the “Sustainability Award” for sustainable and profitable growth. R-Biopharm is cultivating a value-oriented corporate culture and management and is family-run in the second generation. The Chairman of the Board of Directors is Christian Dreher.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Bilder
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Business performance up on previous year LBBW delivers strong result in the first half of the year28.8.2025 08:08:34 CEST | Press release
Stuttgart, Germany Sustained growth: operating profit before tax, excluding integration costs from Berlin Hyp, increases to €759 million (previous year: €731 million) Successful core business: income improves across all customer segments, with the strongest growth in the Corporate Customers business Allowances for losses on loans and securities slightly below previous year – model adjustments unchanged at €880 million Common equity Tier 1 (CET 1) capital ratio rises to 16.6 percent Outlook confirmed: profit before tax above €1 billion for the full year LBBW has delivered another strong result in a challenging economic environment. Operating profit before taxes, adjusted for expenses from the integration of Berlin Hyp, rose to €759 million, 4 percent above the previous year (€731 million). Including integration effects, the pre-tax profit of €705 million was only slightly below the previous year’s figure. CEO Rainer Neske: “The half-year result shows that LBBW is strategically well posi
VAC and Torngat Metals Announce Strategic Partnership to Strengthen Rare Earth Supply Chain27.8.2025 08:58:22 CEST | Press release
(Hanau/Berlin – August 26, 2025) – VACUUMSCHMELZE (VAC), a global leader in the production of rare earth permanent magnets and Torngat Metals, a Quebec-based rare earths development company, have signed a non-binding Memorandum of Understanding (MOU) to pursue an offtake agreement for Torngat Metals to supply VAC with long-term security of fully traceable and responsibly produced separated rare earth oxides. The MOU was signed in Berlin today by Yves Leduc, CEO of Torngat Metals, and Erik Eschen, CEO of VAC, in the presence of Germany’s Minister for Economic Affairs and Energy Katherina Reiche and Canada’s Minister of Energy and Natural Resources Tim Hodgson. This strategic move underscores Canada and Germany's bilateral collaboration in the area of critical minerals. Both countries are seeking to address the global heavy rare earths crisis while establishing a permanent magnet supply chain independent from China.
Providing a future for the next generation27.8.2025 08:00:00 CEST | Press release
In light of advancing climate change, creating a climate resilience strategy in Germany, Europe and around the world is essential for coming generations. A strategy of this kind demands change in society and the economy towards a sustainable lifestyle and production methods. Scientists from the Pontifical Academies of Sciences and of Social Sciences will debate how this can be achieved, along with experts and young people from European cities and regions, at the European Climate Resilience Summit to be held in Vienna on August 28 and 29. The Bertelsmann Stiftung, the Austrian Academy of Sciences and the European Academies Science Advisory Council are conference partners. The conference will conclude with a Call to Action and an appeal to set up networks and to shape that change.
Dagrofa Denmark joins EMD's Retail Group22.8.2025 11:00:00 CEST | Press release
Following Axfood in Sweden and a new group of Polish retailers, the international retail alliance can now extend its collaboration with the A-brand industry in Scandinavia to encompass the renowned Danish retailer
No Nazi merchandise from Druck18: Laut gegen Nazis e.V. secures trademark rights to Germany's largest online Nazi shop18.8.2025 14:35:31 CEST | Press release
The initiative is part of the award-winning “Rights Against the Right“ campaign by Laut gegen Nazis e.V. and the advertising agency Jung von Matt
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom